TRCT
BOLD

Tower Research Capital (TRC)’s Audentes Therapeutics, Inc BOLD Stock Holding History

Tower Research Capital (TRC)’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,438
Closed -$68K – 4831
2019
Q3 		$68K Buy
2,438
+2,241
+1,138% +$76.5K ﹤0.01% 1581
2019
Q2 		$7K Buy
+197
New +$7.57K ﹤0.01% 2814
2019
Q1 		– Sell
-400
Closed -$9K – 4635
2018
Q4 		$9K Buy
400
+109
+37% +$2.81K ﹤0.01% 2597
2018
Q3 		$12K Buy
+291
New +$10.8K ﹤0.01% 2674
2017
Q4 		– Sell
-2,985
Closed -$84K – 4308
2017
Q3 		$84K Buy
2,985
+2,881
+2,770% +$62.6K 0.01% 1538
2017
Q2 		$2K Buy
104
+4
+4% +$64 ﹤0.01% 2421
2017
Q1 		$2K Sell
100
-312
-76% -$5.05K ﹤0.01% 2720
2016
Q4 		$8K Buy
412
+42
+11% +$725 ﹤0.01% 2813
2016
Q3 		$7K Buy
+370
New +$5.62K ﹤0.01% 2373

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Tower Research Capital (TRC)'s BOLD Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 2,438 shares — an estimated $68K sold.

Tower Research Capital (TRC) first reported a position in BOLD in Q3 2016 and held it in 9 quarters. The position peaked at $84K in Q3 2017. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Tower Research Capital (TRC) reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,438 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $68K.
  • Tower Research Capital (TRC) first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Audentes Therapeutics, Inc position peaked at $84K in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.